IL17A and psoriasis: In this study, we investigated serum levels of IL-6, IL-17A, IFN-α, IFN-γ, and TNF-α in patients with psoriasis before and after treatment with brodalumab, all of whom had previously failed therapy with TNF-α inhibitors.